A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.
11 September 2014: Founders of bio-bean win €500,000 funding for business expansion
UCL graduate Arthur Kay, co-founder of the coffee grounds recycling company bio-bean, has won the Postcode Lottery Green Challenge 2014, winning a prize of €500,000 towards the expansion of his business. More...
We are pleased to confirm that Professor Stephen Caddick has been appointed to the new position on the LEP for a representative of London’s Higher Education sector.
22 November 2013: How to respond when the grand vision becomes a cold reality
New ventures are started for many reasons, with one of the most common routes beginning with someone doing a job they like in a big company and thinking they want to do it for themselves, but where do they go from there, asks Timothy Barnes, Director of UCL Enterprise Operations and UCL Advances. More...
18 October 2013: Business letters: October 20
YOU say that turning university science projects into big companies is mostly impossible (“Imperial needs to pick more winners”, last week). Yet the acquisition of Spirogen by Astra Zeneca for $440m (£272m) last week shows that substantial returns to investors are possible from university research.
Read: The Sunday Times
18 October 2013: UCL and Photobiotics announce partnership to tackle gastric cancer
UCL, Photobiotics pursue new approach to gastric cancer
A new collaboration between University College London (UCL) and PhotoBiotics, a targeted oncology company spun out from Imperial College London in the UK, is looking to develop a multifunctional agent for use in both the diagnosis and treatment of gastric cancer.
16 October 2013: Spirogen sold to AstraZeneca